Terms: = Liver cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Treatment
123 results:
1. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
[TBL] [Abstract] [Full Text] [Related]
2. Sensitization of cholangiocarcinoma cells to chemotherapy through bcrp inhibition with β-caryophyllene oxide.
Ortiz-Rivero S; Peleteiro-Vigil A; Abete L; Lozano E; Hammer HS; Giacomo SD; Abad M; Boix L; Forner A; Reig M; Macias RIR; Pötz O; Marin JJG; Briz O
Biomed Pharmacother; 2024 Jan; 170():116038. PubMed ID: 38141281
[TBL] [Abstract] [Full Text] [Related]
3. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S; Furuya N; Nakamura A; Shiihara J; Nakachi I; Tanaka H; Nakao M; Minato K; Seike M; Sasaki S; Kisohara A; Takeuchi S; Honda R; Takamura K; Kagamu H; Yoshimura K; Kobayashi K; Kikuchi T
Eur J Cancer; 2024 Jan; 197():113469. PubMed ID: 38061214
[TBL] [Abstract] [Full Text] [Related]
4. Polyphyllin I attenuates the invasion and metastasis via downregulating GRP78 in drug-resistant hepatocellular carcinoma cells.
Du H; Wu H; Kang Q; Liao M; Qin M; Chen N; Huang H; Huang D; Wang P; Tong G
Aging (Albany NY); 2023 Nov; 15(21):12251-12263. PubMed ID: 37934581
[TBL] [Abstract] [Full Text] [Related]
5. Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method.
Rysz MA; Kinzi J; Schäfer AM; In-Albon K; Zürcher S; Schmidlin S; Seibert I; Schwardt O; Ricklin D; Meyer Zu Schwabedissen HE
J Pharm Biomed Anal; 2023 Nov; 236():115716. PubMed ID: 37722165
[TBL] [Abstract] [Full Text] [Related]
6. Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M; van Doorn L; Kloet E; van Veggel A; Matic M; de Neijs MJ; Oomen-de Hoop E; van Meerten E; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2023 Nov; 62(11):1589-1597. PubMed ID: 37715926
[TBL] [Abstract] [Full Text] [Related]
7. Saikosaponin D reverses epinephrine- and norepinephrine-induced gemcitabine resistance in intrahepatic cholangiocarcinoma by downregulating ADRB2/glycolysis signaling.
He H; Guo J; Hu Y; Zhang H; Li X; Zhang J; Jin S
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1404-1414. PubMed ID: 37489008
[TBL] [Abstract] [Full Text] [Related]
8. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
Elkateb AS; Nofal S; Ali SA; Atya HB
Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
[TBL] [Abstract] [Full Text] [Related]
9. Effect of Chronic Hepatitis C on the Activity of the Membrane Transporters P-gp and OATP1B1/bcrp on Patients With Different Stages of Hepatic Fibrosis.
Pippa LF; Vieira CP; Caris JA; Rocha A; Marques MP; Garcia CP; Rezende REF; Lanchote VL
Clin Pharmacol Ther; 2023 Jul; 114(1):173-181. PubMed ID: 37070971
[TBL] [Abstract] [Full Text] [Related]
10. Anti-drug resistance, anti-inflammation, and anti-proliferation activities mediated by melatonin in doxorubicin-resistant hepatocellular carcinoma: in vitro investigations.
Hamed AR; Yahya SMM; Nabih HK
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jun; 396(6):1117-1128. PubMed ID: 36651944
[TBL] [Abstract] [Full Text] [Related]
11. The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.
Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Ejlertsen B; Lash TL; Bøggild H; Sørensen HT; Cronin-Fenton D
Cancer Chemother Pharmacol; 2023 Feb; 91(2):157-165. PubMed ID: 36598552
[TBL] [Abstract] [Full Text] [Related]
12. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.
Nio Y; Ishida H; Matsumoto N; Kusumoto S; Kubota Y; Tsunoda T; Sasaki Y; Fujita KI
BMC Pulm Med; 2022 Nov; 22(1):454. PubMed ID: 36451169
[TBL] [Abstract] [Full Text] [Related]
13. Rationally Screened and Designed abcg2-Binding Aptamers for Targeting cancer Stem Cells and Reversing Multidrug Resistance.
Ma Y; Guo Z; Fan C; Chen J; Xu S; Liu Z
Anal Chem; 2022 May; 94(20):7375-7382. PubMed ID: 35544739
[TBL] [Abstract] [Full Text] [Related]
14. Noninvasive Evaluation of Multidrug Resistance via Imaging of abcg2/bcrp Multidrug Transporter in Lung cancer Xenograft Models.
Li C; Yang Q; Chen Z; Qiu Y; Du Y; Wang R; He Q; Yang J; Zhen H; Kang L
Mol Pharm; 2022 Oct; 19(10):3521-3529. PubMed ID: 35427142
[TBL] [Abstract] [Full Text] [Related]
15. ABCB1 limits brain exposure of the KRAS
Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
[TBL] [Abstract] [Full Text] [Related]
16. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Liao M; Jeziorski KG; Tomaszewska-Kiecana M; Láng I; Jasiówka M; Skarbová V; Centkowski P; Ramlau R; Górnaś M; Lee J; Edwards S; Habeck J; Nash E; Grechko N; Xiao JJ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):887-897. PubMed ID: 34370076
[TBL] [Abstract] [Full Text] [Related]
17. Role of ATP-binding Cassette Transporters in Sorafenib Therapy for Hepatocellular Carcinoma: An Overview.
Estevinho MM; Fernandes C; Silva JC; Gomes AC; Afecto E; Correia J; Carvalho J
Curr Drug Targets; 2022; 23(1):21-32. PubMed ID: 33845738
[TBL] [Abstract] [Full Text] [Related]
18. Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Egawa T; Masuzawa K; Nakayama S; Maeda I; Tsunematsu S; Suzuki Y; Suzuki Y
Intern Med; 2021 Oct; 60(20):3273-3277. PubMed ID: 33840693
[TBL] [Abstract] [Full Text] [Related]
19. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma treatment.
Liang X; Wang Y; Shi H; Dong M; Han H; Li Q
Int J Nanomedicine; 2021; 16():2569-2584. PubMed ID: 33833512
[TBL] [Abstract] [Full Text] [Related]
20. Overexpression of Human ABCB1 and abcg2 Reduces the Susceptibility of cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat.
Wu CP; Hung CY; Lusvarghi S; Chang YF; Hsiao SH; Huang YH; Hung TH; Yu JS; Ambudkar SV
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807514
[TBL] [Abstract] [Full Text] [Related]
[Next]
